162 related articles for article (PubMed ID: 22127193)
1. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G
J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
[No Abstract] [Full Text] [Related]
2. [Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].
Savel'eva MI; Sychev DA; Kazakov RE; Ignat'ev IV; Tishenova A; Gasanov NA; Ramenskaia GV; Kukes VG
Klin Med (Mosk); 2008; 86(11):22-8. PubMed ID: 19177788
[TBL] [Abstract][Full Text] [Related]
3. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
4. CYP 2D6 polymorphism and antipsychotic therapy.
Plesnicar BK; Dolzan V; Zalar B
Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
[TBL] [Abstract][Full Text] [Related]
5. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
6. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
Sjöqvist F; Eliasson E
Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
[TBL] [Abstract][Full Text] [Related]
8. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
Steimer W
Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
Peñas-Lledó EM; Trejo HD; Dorado P; Ortega A; Jung H; Alonso E; Naranjo ME; López-López M; Llerena A
Mol Psychiatry; 2013 Jan; 18(1):8-9. PubMed ID: 22733128
[No Abstract] [Full Text] [Related]
11. Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?
Haffen E; Vandel P; Paintaud G; Broly F; Vandel S; Bonin B; Bizouard P; Sechter D; Bechtel PR
Eur J Clin Pharmacol; 2000; 55(11-12):877-9. PubMed ID: 10805068
[No Abstract] [Full Text] [Related]
12. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
13. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 phenotype prediction from genotype: which system is the best?
Kirchheiner J
Clin Pharmacol Ther; 2008 Feb; 83(2):225-7. PubMed ID: 18202689
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic drug monitoring of new antidepressives and antipsychotics].
Härtter S; Hiemke C
Med Monatsschr Pharm; 2003 May; 26(5):160-2. PubMed ID: 12784506
[No Abstract] [Full Text] [Related]
16. Tolerance to desvenlafaxine in rapid metabolizing depressed patients.
Parker GB; Brotchie HL; Hyett M
Int Clin Psychopharmacol; 2011 Mar; 26(2):84-7. PubMed ID: 21119521
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
Vandel P
World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
[TBL] [Abstract][Full Text] [Related]
18. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
20. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.
Chou WH; Yan FX; de Leon J; Barnhill J; Rogers T; Cronin M; Pho M; Xiao V; Ryder TB; Liu WW; Teiling C; Wedlund PJ
J Clin Psychopharmacol; 2000 Apr; 20(2):246-51. PubMed ID: 10770465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
